News Denali's ALS programme suffers another setback Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.
News SMA treatment with Evrysdi 'could start prenatally' Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.
News US/EU regulators start review of Biogen's high-dose Spinraza Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?
News Algorithm spots common sleep disorder linked to dementia An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.
News Denali slides after ALS drug flunks clinical test Another clinical trial setback disappoints the ALS patient community, this time involving Denali's eIF2B agonist DNL343.
News uniQure rockets on map to market for Huntington's therapy uniQure says it has reached agreement with the FDA on a pathway to accelerated approval for its much-anticipated Huntington's disease gene therapy.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
